The results send a ‘clear, pragmatic message’ of IL-17 inhibition’s greater potency over IL-12/23 inhibition, an expert says.

CHICAGO -- Plaque psoriasis drug deucravacitinib (Sotyktu) now looks likely to win a psoriatic arthritis (PsA) indication in ...

Patients with psoriatic arthritis who received GLP-1 receptor agonists exhibited lower risks for mortality and cardiovascular ...

Patients with PsA have a higher prevalence of MetS compared with members of the general population and individuals with other inflammatory arthropathies.

Previously swollen joints in psoriatic arthritis have a nearly threefold increased likelihood of swelling again at the same ...

What are called autoimmune diseases can affect just about every part of the body – and tens of millions of people. While most ...

Following a transformational investment from the Krembil Foundation, York has officially launched the Psoriatic Arthritis Collaborative and Applied Research Excellence (PsA CARE) Hub, the first ...

Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to ...

Under the partnership between Alvotech and Advanz Pharma, Alvotech is responsible for the development and commercial supply of Gobivaz ®, while Advanz Pharma holds the registration and exclusive ...

Current therapies such as biological DMARDs showed promising results in treating rheumatoid arthritis patients, and market penetration is expected to be more in the future and expected to drive market ...

GLP-1RA use was associated with a lower incidence of rheumatic diseases such as rheumatoid arthritis, gout, and osteoarthritis relative to DPP-4is.

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best NYSE stocks to buy and hold for the next decade. On October 27, Bristol Myers Squibb announced new Week 52 data from its pivotal Phase 3 ...